

## **Record contracting year for the Synektik Group. Hospitals gear up for the next wave of investment**

**In the 2025 financial year (October 2025 – September 2026), the Synektik Group secured orders for the supply of medical equipment with a total value of approximately PLN 493 million, 26% more than a year earlier. In the fourth quarter alone, the value of new orders was approximately PLN 70 million. At the end of September, the Group's backlog stood at more than PLN 43 million, and the value of active bids at approximately PLN 200 million.**

*"We are closing the best year in the Group's history in terms of orders secured. After just three quarters, their value exceeded PLN 420 million and was higher than in the entire previous financial year. Lower contracting in the fourth quarter compared with the same period last year, when the value of contracts signed reached PLN 145 million, does not change this picture. It is largely the result of the funding calendar for healthcare investments. In July–September, hospitals were settling projects financed from the National Recovery Plan (KPO) with the Ministry of Health, while at the same time preparing applications for funding from other sources. This cycle is also reflected in our bid portfolio. A year ago, its value was very high, as hospitals were then running KPO-funded tenders. We converted a significant part of those bids into orders over the year, which translated into a record result. Today, we are building our portfolio for the next programmes,"* says **Dariusz Korecki, Vice President of the Management Board and CFO of Synektik.**

*"Significant spending on hospital modernisation is planned for the coming years, and we are well positioned to take part in it. Under the Medical Fund alone, this includes PLN 4.5 billion for strategic oncology projects to be completed by 2029 and more than PLN 1.1 billion in the ongoing competition for investments related to hospital consolidation. On top of that, there is a new sub-fund dedicated to infrastructure for national defence needs. Further funding comes from the National Oncology Strategy and EU programmes, including FEnIKS (European Funds for Infrastructure, Climate and Environment) and regional programmes. At the end of September, the value of our active bids was approximately PLN 200 million, which provides a solid base for securing further contracts. We expect the value of orders in the coming quarters to be significantly higher than in the quarter just ended,"* comments **Cezary Kozanecki, CEO of Synektik.**

\*\*\*

### **About Synektik Group**

Synektik Group is a leading manufacturer of advanced radiopharmaceutical products and IT solutions (including the Zbadani.pl medical platform and a radiation dose monitoring application), a provider of maintenance and measurement services, and a distributor of innovative medical devices used in diagnostics and therapy in the fields of radiology, oncology, cardiology and neurology.

Synektik has three radiopharmaceutical production plants in Poland, one of which also serves as an R&D centre working on, among other things, improving existing radiopharmaceutical products. The Group is also developing its own clinical research centre. At the same time, Synektik remains a leading supplier of special



radiopharmaceuticals in Poland, used, among other things, in the diagnosis of hepatocellular carcinoma and prostate cancer and its bone metastases.

Within its medical device distribution segment, the Group works with more than a dozen global manufacturers of diagnostic and therapeutic products. This broad product portfolio, together with the expertise it has built up, allows the company to offer, among other things, the turnkey construction of hybrid operating rooms.

For 25 years, the Group has been bringing the latest technologies to healthcare in Poland. Synektik is, among other things, the exclusive distributor of robotic systems for minimally invasive surgery, robots for micro- and supermicrosurgery, non-invasive ultrasound-based neurosurgery equipment (MRgFUS for the treatment of essential tremor and tremor caused by Parkinson's disease), stereotactic radiosurgery of the head, brain and neck, non-invasive liver tumour destruction technology (so-called histotripsy), and systems for the automation and robotisation of hospital pharmacies (including BD Rowa and Apoteca). The Group is also expanding its distribution activities for selected medical technologies into other countries in the region and currently operates in 7 countries: Poland, the Czech Republic, Slovakia, Lithuania, Latvia, Estonia and Ukraine.

More information: [www.synektik.pl](http://www.synektik.pl)

\*\*\*

## **Contact**

NBS Communications

e-mail: [synektik@nbs.com.pl](mailto:synektik@nbs.com.pl)

Piotr Wojtaszek | +48 500 202 355

Krzysztof Woch | + 48 516 173 691

Maciej Szczepaniak | +48 514 985 845